Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE®...
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson’s Disease (PD or...
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE®...
Emittent / Herausgeber: CLINUVEL PHARMACEUTICALS LTD / Schlagwort(e): Sonstiges Biotech-Unternehmen CLINUVEL launcht Photomedizin-Stiftung bei Event von Lady Gaga 07.03.2024 / 09:00 CET/CEST...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level...
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE®...
MELBOURNE, Australia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Results released today from a clinical study have shown that the drug afamelanotide can reduce critical skin damage caused by ultraviolet...
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the...
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.025 | 0.352112676056 | 7.1 | 7.215 | 6.925 | 4148 | 7.02838492 | DE |
| 4 | -0.24 | -3.25865580448 | 7.365 | 7.515 | 6.63 | 8244 | 7.07052497 | DE |
| 12 | -1.56 | -17.9620034542 | 8.685 | 8.97 | 6.63 | 8217 | 7.58212214 | DE |
| 26 | -2.18 | -23.428264374 | 9.305 | 9.6649999 | 6.63 | 5898 | 8.04339257 | DE |
| 52 | -2.193 | -23.5350933677 | 9.318 | 10.79 | 6.63 | 6033 | 8.58398226 | DE |
| 156 | -4.07 | -36.3555158553 | 11.195 | 11.395 | 6.63 | 6105 | 8.94421943 | DE |
| 260 | -4.07 | -36.3555158553 | 11.195 | 11.395 | 6.63 | 6105 | 8.94421943 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
